Campaign group Médecins Sans Frontières (MSF) has called on Johnson & Johnson (NYSE: JNJ) to slash the price of its tuberculosis (TB) drug Sirturo (bedaquiline) by 50%.
MSF has warned in a report released at the 49th Union World Conference on Lung Health in The Netherlands, that people with drug-resistant (DR) TB continue to be deprived of today’s best-possible treatment in part because of high drug prices.
"More expensive than previous regimens"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze